Abstract
Our study involved 25 postmenopausal patients (endometrial carcinoma--16, breast (6) and colorectal (3) cancer, aged 56.8 +/- 0.9). All patients were in clinical remission. None had received any specific therapy for at least 12 months. After a laboratory endocrine-genotoxic switch evaluation, 17 patients were given an antidiabetic drug--biguanide metformin--or N-acetylcysteine as antioxidant (8) for 3 months. A checkup was carried out on completion of the course. As a result, hormonal and progenotoxic effects of glucose were found to be inhibited significantly. Much less pronounced was the impact on relevant effects of estradiol which were investigated vis-a-vis nature of blood mononuclear response in vitro. Both isolated and combined administration of said drugs used for endocrine-metabolic rehabilitation is justified.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Acetylcysteine / administration & dosage
-
Acetylcysteine / pharmacology
-
Acetylcysteine / therapeutic use*
-
Aged
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Body Mass Index
-
Breast Neoplasms / metabolism
-
Colonic Neoplasms / metabolism
-
Drug Administration Schedule
-
Endometrial Neoplasms / metabolism
-
Estrogens / metabolism*
-
Female
-
Free Radical Scavengers / administration & dosage
-
Free Radical Scavengers / pharmacology
-
Free Radical Scavengers / therapeutic use*
-
Glucose / metabolism*
-
Humans
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Interleukin-6 / blood
-
Metformin / administration & dosage
-
Metformin / pharmacology
-
Metformin / therapeutic use*
-
Middle Aged
-
Neoplasms / blood
-
Neoplasms / metabolism*
-
Postmenopause
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / blood
Substances
-
Blood Glucose
-
Estrogens
-
Free Radical Scavengers
-
Hypoglycemic Agents
-
Interleukin-6
-
Tumor Necrosis Factor-alpha
-
Metformin
-
Glucose
-
Acetylcysteine